Skip to Content

Anthony Lucci, Jr., M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1484
Houston, TX 77030
Room Number: FCT17.6066

Education & Training

Degree-Granting Education

1991 Texas Tech University School of Medicine, Lubbock, TX, MD, Medicine
1985 The University of Texas at Austin, Austin, TX, BA, Biology

Postgraduate Training

7/1996-7/1998 Surgical Oncology Fellowship, Surgery, John Wayne Cancer Institute, Santa Monica, CA, Donald Morton, M.D.
6/1991-6/1996 Internship/Residency, General Surgery, Mayo Clinic, Rochester, MN, David Farley, M.D.

Board Certifications

2/1997 American Board of Surgery

Selected Publications

Peer-Reviewed Original Research Articles

1. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing Behavior in Clinical Practice in Response to the ACOSOG Z0011 Trial: A Survey of the American Society of Breast Surgeons. Ann Surg Oncol. e-Pub 7/2012. PMID: 22820938.
2. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic Features and Prognosis of Ductal Carcinoma in Situ are Not Adversely Impacted by Initial Large Body Mass. Breast Cancer Res Treat 133(3):1131-41, 6/2012. e-Pub 3/2012. PMID: 22392043.
3. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Ann Surg Oncol. e-Pub 5/2012. PMID: 22622473.
4. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobagyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist. e-Pub 5/2012. PMID: 22584436.
5. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients with Ductal Carcinoma in Situ after Local Excision. J Clin Oncol 30(6):600-7, 2/2012. e-Pub 1/2012. PMCID: PMC3295558.
6. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 130(4):808-16, 2/2012. e-Pub 4/2011. PMCID: PMC3169728.
7. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated Tumor Cells Predict Survival after Neoadjuvant Therapy in Primary Breast Cancer. Cancer 118(2):342-8, 1/2012. e-Pub 6/2011. PMID: 21717428.
8. Krishnamurthy S, Lucci A. Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients. Ann Surg Oncol 18 Suppl 3:263-4, 12/2011. e-Pub 11/2010. PMID: 21057878.
9. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 12/2011. e-Pub 6/2011. PMID: 21713757.
10. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist. e-Pub 12/2011. PMID: 22147002.
11. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ of the Breast with Subsequent Distant Metastasis and Death. Ann Surg Oncol 18(10):2873-8, 10/2011. e-Pub 4/2011. PMID: 21476105.
12. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 9/2011. e-Pub 2/2011. PMID: 21327455.
13. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 7/2011. e-Pub 6/2011. PMCID: PMC3139726.
14. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur J Cancer 47(10):1527-36, 7/2011. e-Pub 2/2011. PMCID: PMC3116032.
15. Singh B, Cook KR, Vincent L, Hall CS, Martin C, Lucci A. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 168(1):e39-49, 6/1/2011. e-Pub 3/26/2010. PMCID: PMC2921551.
16. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of Local-Regional Recurrence following Immediate Breast Reconstruction in Patients with Early Breast Cancer Treated without Postmastectomy Radiotherapy. Plast Reconstr Surg 127(5):1763-72, 5/2011. PMID: 21532405.
17. De Giorgi U, Cohen EN, Gao H, Mego M, Lee BN, Lodhi A, Cristofanilli M, Lucci A, Reuben JM. Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biol Ther 11(9). e-Pub 5/2011. PMID: 21358274.
18. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy can Predict Patient Prognosis and Facilitate Treatment Planning. Ann Surg 253(3):572-9, 3/2011. e-Pub 1/2011. PMID: 21209588.
19. Gainer SM, Lucci A. Oncoplastics: Techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol 103(4):341-7, 3/2011. PMID: 21337569.
20. Krishnamurthy S, Lucci A. Reply to detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. e-Pub 3/2011. PMID: 21437895.
21. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2/2011. e-Pub 12/2010. PMID: 21153052.
22. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 1/2011. e-Pub 8/2010. PMCID: PMC2997136.
23. Hall C, Lucci A. How heterogeneous cell populations, cancer cell dormancy, and minimal residual disease influence the natural history of cancers. Oncology (Williston Park) 25(1):47, 50, 1/2011. PMID: 21361243.
24. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of Stage I-III breast cancer patients. Ann Surg Oncol 17(12):3252-3258, 12/2010. e-Pub 6/2010. PMID: 20559739.
25. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno N, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351-75, Nov-Dec, 11/2010. e-Pub 10/2010. PMID: 20959401.
26. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Ann Surg Oncol 17(11):2899-908, 11/2010. e-Pub 5/2010. PMID: 20443145.
27. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol 17(Suppl 3):280-5, 10/2010. e-Pub 9/2010. PMID: 20853047.
28. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. e-Pub 10/2010. PMID: 20945319.
29. Singh B, Irving LR, Tai K, Lucci A. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 163(2):235-43, 10/2010. e-Pub 5/2010. PMCID: PMC2943002.
30. Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 17(10):2764-72, 10/2010. e-Pub 3/25/2010. PMCID: PMC2943041.
31. Gainer SM, Lee E, Lucci A. The suture scaffold technique for improved cosmesis in partial mastectomy defects. J Surg Oncol 102(2):184-6, 8/1/2010. PMID: 20648592.
32. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early- stage breast cancer. Cancer 116(14):3330-3337, 7/15/2010. e-Pub 5/5/2010. PMID: 20564098.
33. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234-41, 5/2010. e-Pub 2/2010. PMCID: PMC2860044.
34. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27(4):233-40, 4/2010. e-Pub 3/13/2010. PMID: 20229045.
35. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76(3):889-895, 3/2010. PMCID: PMC2892870.
36. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9(1):180, 2010. e-Pub 7/2010. PMCID: PMC2915978.
37. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clin Cancer Res 15(21):6639-48, 11/2009. e-Pub 10/2009. PMCID: PMC2783487.
38. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 11/2009. e-Pub 5/2009. PMID: 19427625.
39. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61, 9/2009. e-Pub 7/2008. PMID: 18663571.
40. Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. Breast J 15(5):483-8, Sep-Oct, 9/2009. e-Pub 7/2009. PMID: 19624418.
41. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231-6, 8/2009. e-Pub 8/2008. PMID: 19482312.
42. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 6/2009. e-Pub 3/2009. PMCID: PMC2755291.
43. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. Ann Surg Oncol 16(6):1606-11, 6/2009. e-Pub 3/2009. PMID: 19280264.
44. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1555-62, 4/2009. e-Pub 2/2009. PMID: 19195040.
45. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-7, 2/2009. e-Pub 3/2008. PMID: 18327638.
46. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 113(1):30-37, 7/2008. PMID: 18457326.
47. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 196(1):81-87, 7/2008. e-Pub 4/2008. PMID: 18436181.
48. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 induces genomic instability BCL2 expression, doxorubicin resistance, and altered cancer initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147(2):240-6, 6/15/2008. e-Pub 3/18/2008. PMID: 18498876.
49. Marulanda GA, Mont MA, Lucci A, Letson GD, Khakpour N. Orthopedic surgery implications of breast cancer. Expert Rev Anticancer Ther 8(6):949-956, 6/2008. PMID: 18533804.
50. Lucci A. Is axillary dissection needed when the sentinel node is positive? No: it is time to rethink axillary lymph node dissection when the sentinel node is positive. J Surg Oncol 97(3):201-2, 3/2008. PMID: 18264979.
51. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 195(3):363-8; discussion 368-9, 3/2008. PMID: 18206850.
52. Mortenson MM, Xing Y, Weaver S, Lee JE, Gershenwald JE, Lucci A, Mansfield PF, Ross MI, Cormier JN. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol 6:63, 2008. PMCID: PMC2464595.
53. Lang JE, Hall CS, Singh B, Lucci A. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther 7(10):1463-72, 10/2007. PMID: 17944570.
54. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE, Giuliano AE. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24). e-Pub 5/2007. PMID: 17485711.
55. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789-3796, 2007. e-Pub 1/2007. PMID: 17213821.

Book Chapters

1. Lucci A, Cristofanilli M. Occult Micrometastasis in Bone Marrow and Blood. In: Advanced Therapy of Breast Disease. In Press.
2. Gainer SM, Lodhi AK, Lucci A. Breast Cancer Occult Micrometastasis in Bone Marrow and Blood. In: Advanced Therapy of Breast Disease, 3rd. Ed(s) Babiera GV, Skoracki RJ, Esteva FJ. People's Medical Publishing House: Shelton, CT, 951-956, 2012.
3. Gainer SM, Yamauchi H, Lucci A. Surgical Therapy for Inflammatory Breast Cancer. In: Inflammatory Breast Cancer: An Update, 1. Ed(s) Ueno N, Cristofanilli M. Springer, 67-74, 2012.
4. Rourke L, Buchholz T, Lucci A. Treatment of Ductal Carcinoma In Situ. In: Advanced Therapy in Surgical Oncology, 1. Ed(s) Pollock R, Curley S, Ross MI, Perrier ND. BC Decker Inc. Hamilton, Ontario, 482-488, 2007.
5. Rosenkranz K, Lucci A. Surgical Treatment of Breast Cancer During Pregnancy. In: Breast Diseases. IOS Press, 2005.
6. Lucci A, Shoher A. Lymph Node Micrometastases. In: Diseases of the Breast. Lippincott, Williams and Wilkins, 2003.

Last updated: 8/13/2013